Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elranatamab in Relapsed/Refractory Multiple Myeloma
NCT06421675Phase 2Recruiting
- Sponsor
- Ontario Clinical Oncology Group
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of elranatamab in multiple myeloma (MM), sponsored by Ontario Clinical Oncology Group. Started Mar 2025; status: recruiting.
02
Drugs
elranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06421675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06421675.